Polyrizon (PLRZ) Long-Term Deferred Tax (2023 - 2025)
Polyrizon's (PLRZ) quarterly Long-Term Deferred Tax came in at $2.5 million in Q4 2025, up 163.29% YoY from $937000.0 in Q4 2024, and up 163.29% on a QoQ basis from $937000.0 in Q4 2024.
Polyrizon (PLRZ) Long-Term Deferred Tax (2023 - 2025) Analysis & Trends
Polyrizon (PLRZ) has 3 years of Long-Term Deferred Tax data on file, last reported at $2.5 million in Q4 2025.
- Quarterly Long-Term Deferred Tax rose 163.29% year-over-year to $2.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 million (up 163.29% YoY) and the FY2025 annual result came in at $2.5 million, up 163.29% from the prior year.
- Long-Term Deferred Tax climbed to $2.5 million in Q4 2025, from $937000.0 in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $2.5 million in Q4 2025 to a low of $633000.0 in Q4 2023.
- A 3-year average of $1.3 million and a median of $937000.0 in 2024 frame the typical range for Long-Term Deferred Tax.
- Annual changes were most pronounced in 2024 — Long-Term Deferred Tax surged 48.03% — and 2025, when it surged 163.29%.
- Tracing PLRZ's Long-Term Deferred Tax over 3 years: stood at $633000.0 in 2023, then surged by 48.03% to $937000.0 in 2024, then surged by 163.29% to $2.5 million in 2025.
- The last three Long-Term Deferred Tax figures came in at $2.5 million (Q4 2025), $937000.0 (Q4 2024), and $633000.0 (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Polyrizon | 7.27 Mn | -4.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.47 Mn |
| Dec 31, 2024 | 937,000.00 |
| Dec 31, 2023 | 633,000.00 |